Thursday, 15 October 2026European Markets

XILAM ANIMATION Stock Bullish Momentum With A 16% Rise In The Last 5 Sessions

Loading stream...

(vianews) - shares of xilam animation (cac 40: xil.pa) rose by a staggering 16.29% in 5 sessions from €22.1 to €25.70 at 17:08 est on friday, following the last session's downward trend. cac 40 is rising 1.44% to €7,396.06, following the last session's downward trend.

about xilam animation

xilam animation operates as an audiovisual production company in france and internationally. the company creates, produces, and distributes original programs for children and adults. it also broadcasts content on television; subscription video on demand streaming platforms, including netflix, disney +, amazon, and nbc universal; and advertising video on demand streaming platforms, such as youtube, facebook, rakuten tv, tubi, and pluto tv. in addition, the company produces animated, short, and feature films. it owns the oggy, cockroaches, zig & sharko, chicky, oggy oggy, oggy next gen, les contes de lupin, moka, mr magoo, trico, and j'ai perdu mon corps brands. the company was incorporated in 1999 and is headquartered in paris, france.

earnings per share

as for profitability, xilam animation has a trailing twelve months eps of €0.32.

pe ratio

xilam animation has a trailing twelve months price to earnings ratio of 80.31. meaning, the purchaser of the share is investing €80.31 for every euro of annual earnings.

more news about xilam animation (xil.pa).

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com